Merck

1. Merck
2013 sales: $5.77 billion

It's not hard to see how Merck's ($MRK) leading the worldwide vaccines market. The New Jersey pharma giant had 5 of the 10 best-selling vaccines in 2013, including Gardasil in the No. 2 spot. Merck's sales of the HPV jab swelled 12% last year to reach $1.8 billion; the vaccine, marketed in Europe by Merck's JV with Sanofi Pasteur, generated $2.17 billion overall.

And Gardasil has gotten some recent boosts that could lift sales further in the not-too-distant future. It recently scored an EU nod for preventing anal cancer, and back in April, the European Commission approved a two-dose regimen that the company said it thinks could expand coverage and increase uptake.

In February, the FDA also accepted Merck's application for V503, a Gardasil follow-up that analysts estimate could pull in $1.9 billion in peak sales. But most of those will come at Gardasil's expense: Leerink Partners estimates peg Gardasil's 2018 sales at just $525 million.

Backing up Gardasil on the current top-sellers list are fellow blockbuster Varivax, ranking 5th with $1.38 billion in 2013 sales; herpes shot Zostavax, which brought in $826 million to earn the 8th spot; rotavirus vaccine RotaTeq, hauling in $691 million to secure 9th place; and Pneumovax, rounding out the top 10 with $653 million.

For more:
Merck JV plans to show up J&J, Sanofi with low-cost cholera vaccine
Merck, Sanofi JV wins anal cancer indication for Gardasil in EU
Merck's RotaTeq, Glaxo's Rotarix cut hospitalizations by up to 94%
Study: Moral concerns lead barriers to Gardasil uptake in college freshmen

Merck
Read more on

Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.